Wanbury Limited has delivered exceptional financial performance in Q3FY26 with net profit surging significantly compared to the previous year. The pharmaceutical company demonstrated remarkable operational efficiency and profitability improvement across key financial metrics, driven by higher API volumes and improved capacity utilization.

Outstanding Profitability Growth

The company achieved remarkable profitability improvement with profit after tax reaching ₹15.8 crores in Q3FY26 compared to ₹1.2 crores in Q3FY25, representing an impressive growth of 1194.3%. This exceptional performance reflects strong operating performance, margin expansion, improved cost efficiencies and lower finance costs.

Revenue Performance and Growth

Revenue from operations showed strong growth momentum reaching ₹162.4 crores in Q3FY26 compared to ₹133.5 crores in Q3FY25, marking a year-on-year growth of 21.7%. This revenue expansion was driven by higher API volumes, improved capacity utilization at key manufacturing facilities and steady performance in the formulations business.

EBITDA Performance and Margin Expansion

The company demonstrated remarkable operational efficiency with EBITDA reaching ₹26.9 crores in Q3FY26 compared to ₹14.8 crores in Q3FY25, representing strong growth of 81.7%. The EBITDA margin expanded significantly to 16.5% from 11.0% year-on-year, led by operating leverage, better procurement strategies, higher product yields and enhanced solvent recovery systems.

Nine-Month Performance Momentum

For the nine months ended December 31, 2025, Wanbury maintained strong momentum with profit after tax of ₹44.4 crores compared to ₹10.3 crores in the corresponding period, marking a substantial increase of 332.5%. Revenue from operations for the nine-month period stood at ₹485.7 crores versus ₹427.5 crores in the previous year, reflecting growth of 13.6%.

Business Highlights and Strategic Developments

According to Mr. Mohan Rayana, Director of Wanbury Ltd., the company achieved commercial invoicing and shipment to European customers for high potent anaesthetic API from its cutting-edge Tanaku facility in Q3FY26. The company is well positioned for growth with upcoming new product launches including Antidiabetic, Anticoagulant, Cough suppressant and Antidepressant products. The formulations business remained EBITDA positive with good results from the recent launch of nutritional supplement C-Red and other products.

Manufacturing Infrastructure and Capabilities

The company operates two USFDA approved API facilities with 386 KL cumulative reactor capacity and has achieved highest-ever operational EBITDA of ₹80 crore. The API business maintains 80%+ export top line with emphasis on developed markets including EU, Brazil and US. The formulations business is rebuilding legacy brand formulations in India with 10+ active brands across key therapeutic categories such as Anti cold & cough, Anti-infective, Anti-inflammatory, Supplements and Orthopaedic segments.

Wanbury Limited has reached a significant commercial milestone with the completion of its first sales invoicing and commercial shipment of newly launched anaesthetic Active Pharmaceutical Ingredients (APIs) on January 30, 2026. The company successfully shipped products to a European customer from its Tanuku facility, demonstrating rapid market adoption and operational excellence following the recent product launch.

Commercial Milestone and Market Validation

The company has achieved a game-changing milestone with official confirmation of first sales, customer invoicing, and commercial shipment to a European customer for its newly commercialized anaesthetic API from the Tanuku facility. This achievement validates global demand and positions Wanbury for high-growth acceleration in the specialized pharmaceutical ingredients market.

Leadership Perspective and Growth Outlook

Mr. Mohan Rayana, Whole-time Director of Wanbury Limited, declared that "First sales confirmed, invoicing and product shipment completed, production scaling fast. Our expansion momentum positions us for exponential growth and market leadership." The rapid transition from product launch to commercial shipment reflects the company's effective market penetration strategy and operational capabilities.

Revenue Projections and Strategic Impact

The successful commercial shipment supports Wanbury's ambitious revenue target of ₹100.00 crore from these anaesthetic APIs by FY 2026-27. Just months after launching commercial production, the company has secured orders and completed invoicing, demonstrating strong market demand for these specialized pharmaceutical ingredients.

Manufacturing Excellence and Market Position

The successful completion of first commercial shipment from the Tanuku facility demonstrates Wanbury's operational excellence and market-leading product quality. The facility's USFDA and EUGMP approvals enable the company to serve global markets, with this European shipment marking the beginning of international market penetration for the new anaesthetic API portfolio. This success story is set to multiply as the company ramps up production capacity at Tanuku, strengthening Wanbury's position in the specialized pharmaceutical ingredients market.